Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition
Completion Of $425m Deal Comes Shortly After FTC Approved The Transaction
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.
